The News
The leadership vacuum at the FDA won’t be filled anytime soon.
The White House’s last-minute decision to pull the nomination of Heidi Overton leaves the chances of Congress acting during the lame duck around zero, with the Senate health committee’s chair Bill Cassidy, R-La., predicting the job will “fall to the Senate Democrats.” The White House has a slim chance of finding a nominee who supports President Donald Trump’s health agenda and who could win support from the new Senate majority.
Former FDA officials told me they expect a string of acting commissioners to fill in for the next two years. One potential temporary leader is Sara Brenner, who held the acting title in early 2025 before departing the agency earlier this year to work as a senior counselor for public health at HHS. Another name being floated is Karim Mikhail, the FDA’s top regulator of vaccines and biologics.
The leadership void arrives as Congress takes up industry user fees, a critical source of about half of FDA’s funding. They require approval every five years.
Lawmakers could attach agency reforms to the package. FDA leaders have urged Congress to empower regulators with new authorities to mandate drug recalls and compel drugmakers to share data on their supply chains.